Top

Published in:

Open Access 01-03-2016 | Original Article

Clonidine increases bone resorption in humans

Authors: E. J. Limonard, T. Schoenmaker, T. J. de Vries, M. W. Tanck, A. C. Heijboer, E. Endert, E. Fliers, V. Everts, P. H. Bisschop

Published in: Osteoporosis International | Issue 3/2016

Abstract

Summary

Inhibition of sympathetic signaling to bone reduces bone resorption in rodents. In contrast, we show that pharmacological reduction of the sympathetic tone increases bone resorption in humans in vivo. This effect does not appear to be mediated via a direct pharmacological effect on the osteoclast.

Introduction

Inhibition of sympathetic signaling to bone reduces bone resorption in rodents. It is uncertain whether a similar role for the sympathetic nervous system exists in humans. The sympathetic tone can be reduced by clonidine, which acts via alpha-2-adrenergic receptors in the brainstem. Our objective was to determine the effect of clonidine on bone turnover in humans.

Methods

The acute effect of a single oral dose of 0.3 mg clonidine on serum bone turnover markers (C-terminal cross-linking telopeptides of collagen type I (CTx), a marker for bone resorption, and procollagen type 1 N propeptide (P1NP), a marker for bone formation) was determined in a randomized crossover design in 12 healthy volunteers, aged 18–70 years. In addition, we assessed the effect of clonidine on the number of tartrate-resistant acid phosphatase–positive multinucleated cells (TRAcP⁺ MNCs) and bone resorption.

Results

CTx concentrations increased after clonidine treatment compared to the control condition (p = 0.035). P1NP concentrations were not affected by clonidine (p = 0.520).

In vitro, clonidine had no effect on the number of TRAcP⁺ MNCs (p = 0.513) or on bone resorption (p = 0.996).

Conclusions

We demonstrated that clonidine increases bone resorption in humans in vivo. This effect does not appear to be mediated via a direct effect on the osteoclast.

Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100(2):197–207CrossRefPubMed

Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111(3):305–317CrossRefPubMed

Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434(7032):514–520. doi:10.1038/nature03398 CrossRefPubMed

Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, Guo XE, Karsenty G (2011) Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med 208(4):841–851. doi:10.1084/jem.20102608 CrossRefPubMedPubMedCentral

Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D (2006) Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 318(3):1118–1127. doi:10.1124/jpet.106.105437 CrossRefPubMed

Kondo H, Togari A (2011) Continuous treatment with a low-dose beta-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88 (1):23–32. doi:10.1007/s00223-010-9421-9

Bonnet N, Benhamou CL, Brunet-Imbault B, Arlettaz A, Horcajada MN, Richard O, Vico L, Collomp K, Courteix D (2005) Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 37(5):622–633. doi:10.1016/j.bone.2005.07.012 CrossRefPubMed

Bliziotes M, McLoughlin S, Gunness M, Fumagalli F, Jones SR, Caron MG (2000) Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 26(1):15–19CrossRefPubMed

Fonseca TL, Jorgetti V, Costa CC, Capelo LP, Covarrubias AE, Moulatlet AC, Teixeira MB, Hesse E, Morethson P, Beber EH, Freitas FR, Wang CC, Nonaka KO, Oliveira R, Casarini DE, Zorn TM, Brum PC, Gouveia CH (2011) Double disruption of alpha2A- and alpha2C-adrenoceptors results in sympathetic hyperactivity and high-bone-mass phenotype. J Bone Miner Res 26(3):591–603. doi:10.1002/jbmr.243 CrossRefPubMed

10.

Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75(5):365–372. doi:10.1007/s00223-004-0222-x CrossRefPubMed

11.

Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case–control study. J Hypertens 24(3):581–589. doi:10.1097/01.hjh.0000203845.26690.cb CrossRefPubMed

12.

Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19(1):19–24. doi:10.1359/JBMR.0301214 CrossRefPubMed

13.

Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292(11):1326–1332. doi:10.1001/jama.292.11.1326 CrossRefPubMed

14.

Levasseur R, Dargent-Molina P, Sabatier JP, Marcelli C, Breart G (2005) Beta-blocker use, bone mineral density, and fracture risk in older women: results from the epidemiologie de l’Osteoporose prospective study. J Am Geriatr Soc 53(3):550–552. doi:10.1111/j.1532-5415.2005.53178_7.x CrossRefPubMed

15.

Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC (2005) Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20(4):613–618. doi:10.1359/JBMR.041202 CrossRefPubMed

16.

Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, Davidson JS, Grey AB (2005) Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90(9):5212–5216. doi:10.1210/jc.2005-0573 CrossRefPubMed

17.

Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL (2007) Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 40(5):1209–1216. doi:10.1016/j.bone.2007.01.006 CrossRefPubMed

18.

Perez-Castrillon JL, Vega G, Abad L, Sanz A, Mendo M, Porrero MG, Duenas A (2007) Effect of beta-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine 74(3):259–262. doi:10.1016/j.jbspin.2006.09.015 CrossRefPubMed

19.

Meisinger C, Heier M, Lang O, Doring A (2007) Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 18(9):1189–1195. doi:10.1007/s00198-007-0354-8 CrossRefPubMed

20.

Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV (2011) Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 48(3):451–455. doi:10.1016/j.bone.2010.10.170 CrossRefPubMed

21.

de Vries F, Souverein PC, Cooper C, Leufkens HG, Van Staa TP (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 80(2):69–75. doi:10.1007/s00223-006-0213-1 CrossRefPubMedPubMedCentral

22.

Veldhuis-Vlug AG, Tanck MW, Limonard EJ, Endert E, Heijboer AC, Lips P, Fliers E, Bisschop PH (2014) The effects of beta-2 adrenergic agonist and antagonist on human bone metabolism: a randomized controlled trial. Bone 71C:196–200. doi:10.1016/j.bone.2014.10.024

23.

Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP (2013) Beta-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. doi:10.1007/s00198-013-2498-z PubMed

24.

Yang S, Nguyen ND, Eisman JA, Nguyen TV (2012) Association between beta-blockers and fracture risk: a Bayesian meta-analysis. Bone 51(5):969–974. doi:10.1016/j.bone.2012.07.013 CrossRefPubMed

25.

Veldhuis-Vlug AG, El MM, Endert E, Heijboer AC, Fliers E, Bisschop PH (2012) Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy. J Clin Endocrinol Metab 97(11):E2093–E2097. doi:10.1210/jc.2012-2823 CrossRefPubMed

26.

Motyl KJ, Rosen CJ (2012) The skeleton and the sympathetic nervous system: it’s about time! J Clin Endocrinol Metab 97(11):3908–3911. doi:10.1210/jc.2012-3205 CrossRefPubMedPubMedCentral

27.

Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF (2011) Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord 12:167. doi:10.1186/1471-2474-12-167 CrossRefPubMedPubMedCentral

28.

de Jong WH, Graham KS, van der Molen JC, Links TP, Morris MR, Ross HA, de Vries EG, Kema IP (2007) Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem 53(9):1684–1693. doi:10.1373/clinchem.2007.087114 CrossRefPubMed

29.

Davison NL, ten Harkel B, Schoenmaker T, Luo X, Yuan H, Everts V, Barrere-de Groot F, de Bruijn JD (2014) Osteoclast resorption of beta-tricalcium phosphate controlled by surface architecture. Biomaterials 35(26):7441–7451. doi:10.1016/j.biomaterials.2014.05.048 CrossRefPubMed

30.

Wing LM, Reid JL, Davies DS, Neill EA, Tippett P, Dollery CT (1977) Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol 12(6):463–469CrossRefPubMed

31.

Keranen A, Nykanen S, Taskinen J (1978) Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol 13(2):97–101CrossRefPubMed

32.

de Vries TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, de Rooij MJ, Mensink EJ, Ruiter DJ, van Muijen GN (1999) Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Br J Cancer 80(5–6):883–891. doi:10.1038/sj.bjc.6690436 CrossRefPubMedPubMedCentral

33.

Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A (2003) Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 1640(2–3):137–142CrossRefPubMed

34.

Togari A (2002) Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 58(2):77–84. doi:10.1002/jemt.10121 CrossRefPubMed

35.

Togari A, Arai M, Kondo A (2005) The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin Ther Targets 9(5):931–940. doi:10.1517/14728222.9.5.931 CrossRefPubMed

36.

Mlakar V, Jurkovic Mlakar S, Zupan J, Komadina R, Prezelj J, Marc J (2015) ADRA2A is involved in neuro-endocrine regulation of bone resorption. J Cell Mol Med. doi:10.1111/jcmm.12505 PubMedPubMedCentral

37.

Schaffler MB, Cheung WY, Majeska R, Kennedy O (2014) Osteocytes: master orchestrators of bone. Calcif Tissue Int 94(1):5–24. doi:10.1007/s00223-013-9790-y CrossRefPubMed

38.

Gil-Ad I, Topper E, Laron Z (1979) Oral clonidine as a growth hormone stimulation test. Lancet 2(8154):1242CrossRefPubMed

39.

Bredella MA, Gerweck AV, Barber LA, Breggia A, Rosen CJ, Torriani M, Miller KK (2014) Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women. Bone 62:29–35. doi:10.1016/j.bone.2014.01.022 CrossRefPubMedPubMedCentral

40.

Fagerholm V, Haaparanta M, Scheinin M (2011) alpha2-adrenoceptor regulation of blood glucose homeostasis. Basic Clin Pharmacol Toxicol 108(6):365–370. doi:10.1111/j.1742-7843.2011.00699.x CrossRefPubMed

Title: Clonidine increases bone resorption in humans
Authors: E. J. Limonard
T. Schoenmaker
T. J. de Vries
M. W. Tanck
A. C. Heijboer
E. Endert
E. Fliers
V. Everts
P. H. Bisschop
Publication date: 01-03-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 3/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-015-3312-x

At a glance: The STEP trials

Springer Medicine

Clonidine increases bone resorption in humans

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Serum 25-hydroxyvitamin D concentration and its determinants in the very old: the Newcastle 85+ Study

Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015

Correlations among four measures of thoracic kyphosis in older adults

Effect of osteoporosis medications on fracture healing

Non-hip and non-vertebral fractures: the neglected fracture sites

Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial